[Effectiveness and safety of brolucizumab in the treatment of neovascular age-related macular degeneration].

Purpose: This study analyzes the effectiveness and safety of brolucizumab in the treatment of neovascular age-related macular degeneration (nAMD) in real clinical practice.

Material And Methods: The study included patients with nAMD who received brolucizumab treatment and evaluated the changes in best-corrected visual acuity (BCVA), central retinal thickness (CRT), macular volume, as well as the number of injections and adverse events.

Result: The group of previously treated patients included 28 subjects (28 eyes) that were switched to brolucizumab with a loading phase.

[Short-term experience of intravitreal brolucizumab in treatment of diabetic macular edema].

Purpose: This study examines the efficacy and safety of brolucizumab in the treatment of diabetic macular edema (DME) in real clinical practice in the Russian Federation.

Material And Methods: The study included 14 consecutive treatment-naïve DME patients, among them 7 males and 7 females (21 eyes in total) with mean age of 65.1±8.

[Short-term efficacy and safety of Brolucizumab for neovascular age-related macular degeneration in the Russian Federation].

Purpose: To analyze the short-term efficacy and safety of Brolucizumab in the treatment of patients with neovascular age-related macular degeneration (nAMD).

Material And Methods: This retrospective pilot study included 154 patients (51 males and 103 females, mean age 73.9±8.